hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06348303 id: PMMD-01 briefTitle: Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg overallStatus: RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2025-03-15 date: 2024-04-04 date: 2024-04-26 name: Primus Pharmaceuticals class: INDUSTRY name: ClinOhio Research Services, LLC briefSummary: Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks. conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Each participant will be enrolled to two (2), single dose, study treatment arms in a crossover design. The treatments will occur consecutively with seven (7) days separating days of dosing. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Single mask of participants. Participants will be prevented from knowing product dose. whoMasked: PARTICIPANT count: 20 type: ESTIMATED name: Metaxalone m640 mg oral tablet name: Metaxalone 800 mg oral tablet measure: Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test). measure: Change from baseline of gait during a stopwatch timed, stand, and walk activity from a seated position along a 30 foot path measure: Change from baseline of correct number of steps taken on a fixed 4 inch wide, 9 feet long path measure: Change from baseline of participants' subjective report of drowsiness on a 10-point scale measure: Change from baseline of reaction to stimulus by computer generated visual prompts measured in milliseconds measure: Change from baseline of participants' reasoning ability to recognize differences in six (6) computer generated shapes for 30 minutes measure: The number of product related adverse events experienced by participants from Visit 2 through Visit 4 sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: ClinOhio Research Institute status: RECRUITING city: Columbus state: Ohio zip: 43213 country: United States name: J Sanders role: CONTACT phone: 614-683-4900 lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06348290 id: JY-JM1899-105 briefTitle: Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-31 date: 2024-09-15 date: 2024-04-04 date: 2024-04-04 name: Jemincare class: INDUSTRY briefSummary: This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects. A total of three cohorts of 72 healthy subjects were planned to be enrolled in each cohort. conditions: Solid Tumor, Adult studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 72 type: ESTIMATED name: JMKX001899 name: Itraconazole name: Midazolam name: Rifampin name: dextromethorphan name: Rosuvastatin name: digoxin measure: maximum concentrations (Cmax ) for plasma measure: area under the curve from time 0 to infinity(AUC0-inf) for plasma measure: area under the curve from time 0 to the last time point (AUC0-t) for plasma sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06348277 id: 121119 briefTitle: Brief App-based Mood Monitoring and Mindfulness Intervention for First-year College Students overallStatus: COMPLETED date: 2018-01-02 date: 2020-04-07 date: 2020-06-17 date: 2024-04-04 date: 2024-04-04 name: Lawrence University class: OTHER briefSummary: The investigators examined whether brief, app-based interventions were helpful in alleviating mental health symptoms during the transition to college. In particular, the investigators were interested in whether a brief mobile-app mindfulness intervention combined with mood monitoring was more effective in alleviating first-year students' psychological distress than mood monitoring alone. conditions: Depression, Anxiety conditions: Self-Injurious Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 130 type: ACTUAL name: Mindfulness plus mood monitoring name: Mood monitoring measure: Depressive Symptoms measure: Anxiety Symptoms measure: Urges to Self-injure measure: Rumination measure: Worry measure: Depressive Symptoms measure: Depressive Symptoms measure: Anxiety Symptoms measure: Anxiety Symptoms measure: Urges to self-injure measure: Urges to self-injure measure: Rumination measure: Rumination measure: Worry measure: Worry sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lawrence University city: Appleton state: Wisconsin zip: 54911 country: United States lat: 44.26193 lon: -88.41538 hasResults: False
nctId: NCT06348264 id: SDC-1 briefTitle: Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma overallStatus: RECRUITING date: 2024-03-30 date: 2029-03-30 date: 2031-03-30 date: 2024-04-04 date: 2024-04-04 name: Peking University First Hospital class: OTHER name: Jiangsu Hengrui Pharmaceutical Co., Ltd. name: Beijing Biote Pharmaceutical Co.,Ltd briefSummary: The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC).
The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years. conditions: Salivary Gland Neoplasm Duct studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 37 type: ESTIMATED name: Rezvilutamide name: Leuprolide Acetate measure: 3-year disease-free survival (DFS) measure: 3-year overall survival (OS) measure: 3-year disease-specific survival (DSS) measure: 3-year distant-metastatic free survival (DMFS) measure: Adverse events measure: 5-year disease-free survival (DFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University First Hospital status: RECRUITING city: Beijing state: Beijing zip: 100034 country: China name: Xueying Ren, MD role: CONTACT phone: +86 10 83572408 email: xy_ren1031@126.com lat: 39.9075 lon: 116.39723 facility: Peking University School and Hospital of Stomatology status: RECRUITING city: Beijing state: Beijing country: China name: Xiaofeng Shan, MD role: CONTACT phone: +86 10 82195390 email: kqsxf@263.net lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06348251 id: STU00219612 briefTitle: FoodSteps for Binge Eating & Food Insecurity overallStatus: RECRUITING date: 2024-03-26 date: 2024-11-30 date: 2024-11-30 date: 2024-04-04 date: 2024-04-04 name: Northwestern University class: OTHER briefSummary: The purpose of this study is to conduct a pilot trial of a mobile intervention that targets binge eating and weight-related behaviors, to determine the feasibility, acceptability, and preliminary efficacy of the intervention among adults with recurrent binge eating, diabetes, and food insecurity. conditions: Binge Eating conditions: Type 2 Diabetes conditions: Food Insecurity studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: FoodSteps measure: Recruitment and retention rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northwestern University Feinberg School of Medicine status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Andrea K Graham, PhD role: CONTACT phone: 312-503-5266 email: andrea.graham@northwestern.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06348238 id: 2074997 briefTitle: Strategies to Improve Well-Being and Diabetes Management overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-28 date: 2027-02-28 date: 2024-04-04 date: 2024-04-04 name: Elizabeth Scharnetzki class: OTHER name: MaineHealth Institute for Research briefSummary: This project aims to implement an adapted self-affirmation intervention among a population of individuals with diabetes to reduce the negative psychosocial impacts of stigma. In a self-affirmation, participants are guiding through a writing exercise writing designed to reinforce sources of self-worth before they encounter or engage in stressful or stigmatizing events. Participants in this study will be asked to complete self-affirmation exercises before their 3-month wellness appointments with their endocrinologists over the course of a year. The main questions the investigators are asking are:
After each appointment and self-affirmation, participants will complete surveys assessing feelings of stigma and motivation to engage in condition management. All participants will already be using continuous glucose monitors. The investigators will compare both survey responses and continuous glucose data between our conditions to assess the efficacy of the self-affirmation intervention. conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 150 type: ESTIMATED name: Self-Affirmation measure: Social Identity Threat Concerns (SITC) Scale measure: Two-Factor Weight Bias Internalization Scale measure: Diabetes Stigma Assessment Scale measure: The Revised Diabetes Self-Management Questionnaire measure: Confidence in Diabetes Self-Care Scale measure: Blood glucose measure: Hemoglobin A1C measure: Patient-reported age measure: Patient Gender measure: Patient Race measure: Patient ethnicity measure: Patient's highest level of education completed measure: Household income measure: Zip code measure: Years since diagnosis measure: Diabetes Management Plan measure: Physical activity measure: Continuous glucose monitor use measure: Height measure: Weight measure: History of weight-based victimization (moderator/covariate) measure: Problem Areas in Diabetes Questionnaire (moderator/covariate) measure: Generalized Anxiety Disorder 7-item (moderator/covariate) measure: Patient Health Questionnaire (PHQ-9) (moderator/covariate) measure: Stigma Consciousness Questionnaire (moderator/covariate) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MaineHealth Institute for Research, Center for Interdisciplinary and Population Health Research city: Westbrook state: Maine zip: 04092 country: United States name: Elizabeth Scharnetzki role: CONTACT phone: 805-340-9716 email: elizabeth.scharnetzki@mainehealth.org lat: 43.67703 lon: -70.37116 hasResults: False
nctId: NCT06348225 id: FY24-10 briefTitle: Post-exercise Hot Water Immersion to Improve Overnight Blood Pressure acronym: ExHT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-04 date: 2024-04-04 name: Providence College class: OTHER briefSummary: The goal of this clinical trial is to test whether putting your legs in a hot bath after exercise improves blood pressure in people with higher blood pressure.
* A day with no exercise or leg bath Researchers will look at their heart rhythm, blood vessels, and blood pressure after each of these trials to see if there are differences, and if exercise and heat together can improve heart health more than exercise or heat alone. conditions: Elevated Blood Pressure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: A repeated-measures design will be used with all participants completing the three acute interventions (exercise, heat, or exercise + heat) as well as a control day. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: It is not possible to mask the participant to treatments (exercise/no exercise, water temperature, etc) or the PI who is monitoring them during treatment. However, all data (hourly blood pressure, heart rate variability, and flow-mediated dilation) will be analyzed by an individual blinded to the trial/intervention. whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Exercise or heat treatment measure: Ambulatory blood pressure measure: Heart Rate Variability measure: Flow-mediated dilation sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-03-28 uploadDate: 2024-03-28T10:14 filename: Prot_SAP_000.pdf size: 198276 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-03-28 uploadDate: 2024-03-28T10:15 filename: ICF_001.pdf size: 162356 hasResults: False
nctId: NCT06348212 id: 2022-11-008C briefTitle: Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID acronym: COVID-19 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-08 date: 2025-12 date: 2024-04-04 date: 2024-04-04 name: Taipei Veterans General Hospital, Taiwan class: OTHER_GOV briefSummary: The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome.
Researchers will compare the probiotic group and the placebo to see if probiotic supplement really make differences. conditions: Long COVID conditions: Brain Fog conditions: Cognitive Change studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Randomization were performed by the provider of probiotic and placebo. The participant will never know their group. The study Investigator and Outcome assessor will not know the groups of participants until they finish recruiting and data processing. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Lactobacillus paracasei PS23 name: microcrystalline cellulose measure: Long covid related symptoms measure: Hospital Anxiety and Depression Scale measure: The Pittsburgh sleep quality index measure: Fatigue Severity Scale measure: GI symptoms measure: Cognitive function-Digit symbol substitution test measure: Cognitive function-The Montreal Cognitive Assessment(MoCA) measure: Cognitive function-Color Trails making Test measure: Cognitive function-Cogstate Brief Battery (CBB) measure: EEG measure: Gut microbiota measure: Fecal metabolite sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06348199 id: SB27-3004 briefTitle: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer overallStatus: RECRUITING date: 2024-03-12 date: 2025-09 date: 2027-03 date: 2024-04-04 date: 2024-04-19 name: Samsung Bioepis Co., Ltd. class: INDUSTRY briefSummary: The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is:
Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda. conditions: Non-small Cell Lung Cancer Stage IV studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 616 type: ESTIMATED name: SB27 name: Keytruda measure: Objective response rate (ORR) at Week 24 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SB Investigative Site status: RECRUITING city: Batumi country: Georgia lat: 41.64228 lon: 41.63392 facility: SB Investigative Site status: RECRUITING city: Tbilisi country: Georgia lat: 41.69411 lon: 44.83368 facility: SB Investigative Site status: RECRUITING city: Jaipur country: India lat: 26.91962 lon: 75.78781 facility: SB Investigative Site status: RECRUITING city: Surat country: India lat: 21.19594 lon: 72.83023 facility: SB Investigative Site status: RECRUITING city: Cluj-Napoca country: Romania lat: 46.76667 lon: 23.6 facility: SB Investigative Site status: RECRUITING city: Craiova country: Romania lat: 44.31667 lon: 23.8 facility: SB Investigative Site status: RECRUITING city: Sibiu country: Romania lat: 45.8 lon: 24.15 facility: SB Investigative Site status: RECRUITING city: Madrid country: Spain lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06348186 id: Fascial Tissue Response briefTitle: Fascial Tissue Response To Manual Therapy: Implications In Long Covid Rehabilitation overallStatus: RECRUITING date: 2024-02-01 date: 2024-04-01 date: 2024-07-31 date: 2024-04-04 date: 2024-04-04 name: University of the State of Santa Catarina class: OTHER name: Larissa Sinhorim briefSummary: According to the World Health Organization (WHO), as of mid-September 2022, more than 21 million Brazilians have recovered from COVID-19. However, post-infection symptoms continue to appear months after the end of the acute infection, a syndrome called long COVID. Therefore, the aim of this study is to investigate the responses of fascia-focused manual therapy in participants with long COVID. conditions: COVID-19 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Guidebook name: Guidebook and Myofascial Reorganization® (RMF). measure: Functioning and disability measure: Biomechanical and tissue viscoelastic properties measure: Work capacity measure: Quality of life measure: Upper limb dysfunctions measure: Balance sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Santa Catarina State University status: RECRUITING city: Florianópolis state: Santa Catarina zip: 88.035-001 country: Brazil name: Larissa Sinhorim role: CONTACT lat: -27.59667 lon: -48.54917 hasResults: False
nctId: NCT06348173 id: 2021-2190 briefTitle: Response and Remission to Treatment With Anti-IL5/IL5R Antagonists overallStatus: COMPLETED date: 2023-06-01 date: 2023-11-30 date: 2023-11-30 date: 2024-04-04 date: 2024-04-04 name: Université de Montréal class: OTHER name: GlaxoSmithKline briefSummary: The aim of this retrospective observational study is to compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original randomized clinical trials.
This study will be performed using the charts of the patients. conditions: Asthma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 109 type: ACTUAL name: Mepolizumab measure: Response to IL5/IL5R antagonists one year after cohort entry among subjects fulfilling and not fulfilling the original RCT inclusion criteria measure: Remission rate with IL5/IL5R antagonists one year after cohort entry in subjects fulfilling and not fulfilling the original RCT inclusion criteria sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital du Sacré-Coeur de Montréal city: Montréal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06348147 id: LCCC2323 briefTitle: Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-05 date: 2028-08 date: 2024-04-04 date: 2024-04-10 name: UNC Lineberger Comprehensive Cancer Center class: OTHER briefSummary: This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing. conditions: Newly Diagnosed Multiple Myeloma conditions: Multiple Myeloma conditions: Autologous Stem Cell Transplantation studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Daratumumab name: Lenalidomide name: Bortezomib name: Dexamethasone measure: The rate of achievement of bone marrow minimal residual disease (MRD) negativity measure: Progression Free Survival (PFS ) measure: Stringent complete response (sCR) measure: Overall Survival (OS) measure: Therapeutic discontinuation measure: Time to first response measure: Time to best response measure: Maximum depth of response (from PR to CR, including sCR) measure: Overall response rate (ORR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UNC Lineberger Comprehensive Cancer Center city: Chapel Hill state: North Carolina zip: 27516 country: United States name: Ralph L Dessieu role: CONTACT email: ralph-lyne_dessieu@med.unc.edu name: Samuel M Rubinstein, MD, MSCI role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06348134 id: IRB23-0502 briefTitle: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2034-07-01 date: 2036-07-01 date: 2024-04-04 date: 2024-04-04 name: University of Chicago class: OTHER briefSummary: Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery. conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast conditions: HER2-positive Breast Cancer conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 74 type: ESTIMATED name: Trastuzumab emtansine name: Pertuzumab Injection name: Docetaxel name: Tamoxifen name: Letrozole name: Goserelin measure: Pathological Complete Response measure: Reported Adverse Events and clinical/medical records of participants measure: Percentage of participants who are suitable for breast-conserving surgery measure: Event-free survival duration reported among participants measure: Quality of life reported among study participants measure: Genetic and epigenetic factors associated with breast cancer in Nigeria sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago city: Chicago state: Illinois zip: 60615 country: United States name: Olufunmilayo Olufunmilayo role: CONTACT phone: 773-702-1632 email: folopade@medicine.bsd.uchicago.edu lat: 41.85003 lon: -87.65005 hasResults: False